Clinical Trials /

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

NCT02120222

Description:

This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing.

Related Conditions:
  • Melanoma
Recruiting Status:

Unknown status

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
  • Official Title: A Phase 1 Expansion Cohort Evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Unresectable Melanoma

Clinical Trial IDs

  • ORG STUDY ID: OSU-13124
  • SECONDARY ID: NCI-2014-00676
  • NCT ID: NCT02120222

Conditions

  • Recurrent Melanoma

Interventions

DrugSynonymsArms
selinexorCRM1 nuclear export inhibitor KPT-330, KPT-330, selective inhibitor of nuclear export KPT-330, SINE KPT-330Treatment (selinexor)

Purpose

This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To estimate safety of KPT-330 (selinexor) in patients with melanoma at the maximum
      tolerated dose (MTD) defined by the phase 1 study.

      SECONDARY OBJECTIVES:

      I. To determine the clinical benefit rate (CBR) (complete response, partial response, and
      stable disease) of patients with unresectable melanoma.

      II. To assess the efficacy at the MTD as measured by progression free survival (PFS) in
      patients with melanoma.

      TERTIARY OBJECTIVES:

      I. To validate nuclear transport inhibition resulting from treatment. II. To assess if v-raf
      murine sarcoma viral oncogene homolog B1 (BRAF), neuroblastoma RAS viral (v-ras) oncogene
      homolog (NRAS), or platelet-derived growth factor receptor, beta polypeptide (PDGFRB)
      mutational status impacts response.

      III. To assess alteration in signaling pathways as a result of therapy with KPT-330.

      IV. To assess immunologic changes resulting from treatment with KPT-330.

      OUTLINE:

      Patients receive selinexor orally (PO) twice weekly (BIW). Courses repeat every 4 weeks in
      the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 1 year
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (selinexor)ExperimentalPatients receive selinexor PO BIW. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Blood will be collected for correlative studies to perform pK (pharmacokinetics) and pDn (pharmacodynamics) analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
  • selinexor

Eligibility Criteria

        Inclusion Criteria:

          -  Written informed consent in accordance with federal, local, and institutional
             guidelines

          -  Patients with unresectable melanoma

          -  Patients must have received a biologic therapy (e.g. interleukin 2) and a BRAF and/or
             MEK inhibitor (if tumor contains the V600E or V600K mutation) for 628 metastatic
             disease. If patient did not receive such agents, rationale for not treating the
             patients with the 629 agent must be cleared with the study PI (ie no V600e/k BRAF
             mutation or patient with autoimmunity, thus 630 not eligible for biologic therapy).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Total white blood cell (WBC) count >= 3000/mm^3

          -  Absolute neutrophil count (ANC) >= 1500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Bilirubin < 2 times the upper limit of normal (ULN) (except patients with Gilbert's
             syndrome who must have a total bilirubin of < 3 times ULN)

          -  Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological
             and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable

          -  Estimated creatinine clearance of >= 50 mL/min, calculated using the formula of
             Cockroft and Gault

          -  Female patients of child-bearing potential must agree to use dual methods of
             contraception and have a negative serum pregnancy test at screening, and male patients
             must use an effective barrier method of contraception if sexually active with a female
             of child-bearing potential; acceptable methods of contraception are condoms with
             contraceptive foam, oral, implantable or injectable contraceptives, contraceptive
             patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is
             surgically sterilized or post-menopausal; for both male and female patients, effective
             methods of contraception must be used throughout the study and for three months
             following the last dose

        Exclusion Criteria:

          -  Patients who are pregnant or lactating

          -  Radiation, chemotherapy, immunotherapy or any other systemic anticancer therapy =< 2
             weeks prior to initiation of therapy

          -  Major surgery within four weeks before initiation of therapy

          -  Unstable cardiovascular function:

               -  Symptomatic ischemia, or

               -  Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular
                  tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular (AV)
                  block or asymptomatic left anterior fascicular block [LAFB]/right bundle branch
                  block [RBBB] will not be excluded)

               -  Congestive heart failure (CHF) of New York Heart Association (NYHA) class >= 3,
                  or

               -  Myocardial infarction (MI) within 3 months of initiation of therapy

          -  Uncontrolled active infection within one week prior to first dose

          -  Known to be human immunodeficiency virus (HIV) seropositive

          -  Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C
             virus (HCV) ribonucleic acid (RNA) or HBsAg (hepatitis B virus [HBV] surface antigen)

          -  Patients with active central nervous system (CNS) malignancy

               -  Asymptomatic small lesions are not considered active

               -  Treated lesions may be considered inactive if the patient is able to taper off
                  steriods without any recurrent neurologic symptoms.

          -  Patients will be excluded if they have had a major resection of the bowel that could
             influence absorption, inflammatory bowel disease, or other gastrointestinal conditions
             with increased risk of perforation, history of abdominal fistula, gastrointestinal
             perforation within 28 days prior to beginning study treatment

          -  Grade >= 2 peripheral neuropathy within 14 days prior to initiation of therapy

          -  History of seizures, movement disorders or cerebrovascular accident within the past 5
             years

          -  Patients with known macular degeneration or uncontrolled glaucoma

          -  In the opinion of the investigator, patients who are significantly below their ideal
             body weight

          -  Serious psychiatric or medical conditions that could interfere with treatment

          -  Participation in an investigational anti-cancer study within 3 weeks prior to
             initiation of therapy

          -  Concurrent therapy with approved or investigational anticancer therapeutic
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Incidence of adverse events graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
Time Frame:28 days
Safety Issue:
Description:Types of toxicities, incidences and severity will be summarized by descriptive statistics such as frequencies/proportions.

Secondary Outcome Measures

Measure:CBR (complete response, partial response, stable disease or stable disease) using Response Evaluation Criteria in Solid Tumors
Time Frame:Up to 1 year
Safety Issue:
Description:
Measure:PFS
Time Frame:From date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause or last contact, assessed up to 1 year
Safety Issue:
Description:Kaplan-Meier method will be used to assess the PFS.
Measure:Change in tumor markers by immunohistochemistry
Time Frame:Baseline to up to 1 year
Safety Issue:
Description:Markers with continuous numerical data will be analyzed using linear mixed effects models (LMEMs). Binary markers (presence vs. absence) will be summarized by proportions and the confidence intervals will be calculated. Marker changes by mutation groups in plots will be presented. To correlate the marker changes with response, mainly summary statistics and plots will be used given the potentially small subgroups.

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Kari Kendra

Trial Keywords

  • melanoma

Last Updated

July 11, 2017